Witkowski M, et al. - This review examined the relative efficacy and safety of once-weekly semaglutide vs glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with type 2 diabetes (T2D) inadequately controlled on 1–2 oral anti-diabetic drugs (OADs). Data at 24 ± 4 weeks were extracted for efficacy and safety outcomes (feasible for analysis in a NMA), which included the key outcomes of change from baseline in glycated hemoglobin (HbA1c), systolic blood pressure (SBP), and weight, as well as discontinuation due to adverse events (AEs). It was discovered that once-weekly semaglutide 1.0 mg as an add-on to 1–2 OADs was the most efficacious GLP-1 RA with regard to the reduction of HbA1c and weight from baseline after 6 months of treatment. Once-weekly semaglutide appeared to be well tolerated and not related to an increase in discontinuations due to AEs vs other GLP-1 RAs.